Area of research
Surgery · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Lipoproteins and Cardiovascular Health, Diabetes, Cardiovascular Risks, and Lipoproteins, Cancer, Lipids, and Metabolism, and Lipid metabolism and disorders.
Target Populations for Novel Triglyceride-Lowering Therapies
Challenges in achieving LDL cholesterol targets and novel approaches to lipid lowering
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
The Off-Treatment Effects of Olpasiran on Lipoprotein(a) Lowering
Hypertriglyceridemia and Multiorgan Disease Among U.S. Adults
Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings
Temporal Effects of Plozasiran on Lipids and Lipoproteins in Persistent Chylomicronemia
Evinacumab in severe hypertriglyceridemia with or without lipoprotein lipase pathway mutations: a phase 2 randomized trial
ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases
The contribution of amyloid deposition in the aortic valve to calcification and aortic stenosis
Incident CHD and ischemic stroke associated with lipoprotein(a) by levels of Factor VIII and inflammation
Sex differences in incident atherosclerotic cardiovascular disease events among women and men with HIV
Lipoprotein(a) and the Risk for Recurrent Atherosclerotic Cardiovascular Events Among Adults With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease
Alcohol Consumption and Cardiovascular Health
Lipoprotein(a) and the Risk for Coronary Heart Disease and Ischemic Stroke Events Among Black and White Adults With Cardiovascular Disease
Lipid-Lowering Therapy Use and Intensification Among United States Veterans Following Myocardial Infarction or Coronary Revascularization Between 2015 and 2019
Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA/ACC multi-society cholesterol guideline
Use of Lipid-Lowering Therapies Over 2 Years in GOULD, a Registry of Patients With Atherosclerotic Cardiovascular Disease in the US
Risk for ischemic stroke and coronary heart disease associated with migraine and migraine medication among older adults
Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment
Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction
Long-Term Levels of LDL-C and Cognitive Function: The CARDIA Study
Risk for recurrent cardiovascular disease events among patients with diabetes and chronic kidney disease
Factors Associated With PCSK9 Inhibitor Initiation Among US Veterans
The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD
Evinacumab for Homozygous Familial Hypercholesterolemia
Evinacumab in Patients with Refractory Hypercholesterolemia
Atherosclerotic Risk and Statin Use Among Patients With Peripheral Artery Disease
Sex Differences in Incident and Recurrent Coronary Events and All-Cause Mortality